Clinical Trials Sponsored by Ipsen

Total 405 results

Ipsen

Completed

Dysport® Adult Upper Limb Spasticity Extension Study

Nervous System Disorders

United States, France, Belgium, Hungary, Poland, Italy, Czechia, Russian Federation, Slovakia
Ipsen

Terminated

Comparing Lower-concentration Dysport Treatment Targeted to the Neuromuscular Junction With Current Clinical Practice (NMJ)

Arm Spasticity

Sweden, Norway, Denmark, Finland
Ipsen

Completed

Safety and Efficacy Study of Dysport RU and Glabellar Lines

Glabellar Frown Lines

Germany, France
Ipsen

Terminated

Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2) (SSTR2+)

Small Cell Lung Cancer and Breast Cancer

United States, Austria, France, Switzerland, Germany, United Kingdom, Belgium
Ipsen

Withdrawn

Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patients With Locally Advanced or Metastatic Pancreatic or Colorectal Cancer.

Colorectal Cancer | Pancreatic Ductal Adenocarcinoma

Belgium, France
Ipsen

Completed

Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort (AboLiSh)

Adult Lower Limb Spasticity

United States, Australia, Brazil, Canada, France, Germany, Italy, Poland, Russian Federation
Ipsen

Completed

Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination (CARINA)

Advanced Renal Cell Carcinoma (aRCC)

United Kingdom
Ipsen

Completed

Study Assessing Adult Subjects Affected With Upper and/or Lower Limb Spasticity Treated With Botulinum Neurotoxin Type A (RESULT)

Spasticity

Italy
Ipsen

Terminated

Dysport in Vulvodynia Phase II Study (DYVINIA)

Vulvodynia

United States, Canada
Ipsen

Completed

Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs (EXPLAIN)

Gastroenteropancreatic Neuroendocrine Tumors

Finland, Norway, Sweden, Denmark, Latvia, Lithuania, Estonia
Ipsen

Completed

Dysport in Hallux Abducto Valgus (HAV) Phase IIa (DYSTANCE)

Hallux Abducto Valgus

United States
Ipsen

Completed

Programme of Acromegaly Screening in Patients With Associated Somatic Disorders (ACROSCREEN)

Acromegaly

Russian Federation
Ipsen

Terminated

Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer (TasQ003)

Prostatic Neoplasms, Castration-Resistant

China, Korea, Republic of, Taiwan
Ipsen

Completed

Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England

Renal Cell Carcinoma

United Kingdom
Ipsen

Completed

A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients. (PRIORITI)

Prostate Cancer

China, Russian Federation
Ipsen

Terminated

Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome (CAMPANULA)

Carcinoid Syndrome

Spain, Belgium, Ireland, Czechia, Israel, France, United Kingdom, Latvia, Germany, Russian Federation, Slovakia, Italy, Netherlands, Finland, Austria, Poland, Sweden, Ukraine
Ipsen

Withdrawn

Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice (NETways)

Neuroendocrine Tumors

Poland
Ipsen

Completed

Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport® (APPEAL)

Glabellar Lines

Australia, Brazil, Czechia, Kazakhstan, Lebanon, Russian Federation, Turkey, Ukraine
Ipsen

Completed

A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea (SYMNET)

Neuroendocrine Tumors | Carcinoid Syndrome

France, Italy, United Kingdom, Poland, Spain, Hungary, Czechia, Israel
Ipsen

Terminated

Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment

Thyroid-Associated Ophthalmopathy

Spain
Ipsen

Terminated

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

Malignant Carcinoid Syndrome

United States
Ipsen

Completed

Efficacy Study of Dysport® in the Treatment of Anal Fissure.

Anal Fissure

Czechia, Poland, Romania, Tunisia
Ipsen

Completed

Study to Evaluate Smecta® vs Placebo on the Time to Recovery Following an Acute Diarrhoea Episode in Adults

Diarrhea

Morocco, Tunisia
Ipsen

Completed

Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm

Hemifacial Spasm

China
Ipsen

Completed

Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function

Renal Impairment

Moldova, Republic of, Belgium, Germany, Romania
Ipsen

Terminated

A Prospective, Non-interventional Survey to Evaluate Injection Intervals and Treatment Modalities of Botulinum Toxin A (BoNT-A) in Adult Patients Suffering From Upper Limb Spasticity After Stroke (DECIDE)

Upper Limb Spasticity After Stroke

Belgium
Ipsen

Completed

EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders (TAYPES)

Cognitive Disorders

Russian Federation
Ipsen

Completed

BN80927 in Patients With Advanced Malignant Solid Tumors

Malignant Solid Tumour

France
Ipsen

Completed

Validation of Patient Reported Outcome Measures for Use in Hallux Valgus

Hallux Valgus

United States
Ipsen

Completed

Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq (OPTIMA)

Renal Insufficiency, Chronic | Pituitary Diseases | Dwarfism | Turner Syndrome

France, Germany, Finland, Spain, Belgium, Czechia, Denmark, Greece, Italy, Romania, Russian Federation, Slovakia, Ukraine, United Kingdom
Ipsen

Terminated

A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

Metastatic Castrate Resistant Prostate Cancer

France, Spain, Poland, Belgium, Germany, Italy, Denmark, Lithuania, United Kingdom, Czechia, Hungary
Ipsen

Completed

Effectiveness of Smecta in Combination With Oral Rehydration in the Treatment of Acute Watery Diarrhoea in Infants and Children

Diarrhoea

Malaysia
Ipsen

Completed

Effectiveness of Smecta in the Treatment of Acute Diarrhoea in Children

Diarrhoea

Peru
Ipsen

Terminated

Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer

Prostate Cancer

United Kingdom, Spain, France, Belgium, Poland, Latvia, Lithuania, Ukraine
Ipsen

Terminated

Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly (TULIPIA)

Acromegaly

Belgium, Brazil, Lithuania, Sweden, France, United States, Czechia, Latvia, Mexico, Netherlands, Poland, Romania, Ukraine
Ipsen

Completed

Validation of the Spasticity Related Quality of Life Questionnaire (SQOL-6D)

Spasticity, Muscle

United Kingdom
Ipsen

Completed

Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

Acromegaly

Australia
Ipsen

Completed

Somatuline Autogel: Acromegaly Self/Partner Injection Study

Acromegaly

United Kingdom
Ipsen

Completed

Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects (SOMACROL)

Acromegaly

Spain, Portugal
Ipsen

Withdrawn

Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF)

Idiopathic Short Stature
Ipsen

Terminated

Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?

Cerebral Palsy

United Kingdom
Ipsen

Completed

A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide

Acromegaly

Spain, United Kingdom, Italy, France, Belgium, Hungary, Czechia, Denmark, Poland, Sweden
Ipsen

Completed

Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly

Acromegaly

United States, Germany, Hong Kong, Czechia, France, Hungary, Netherlands, United Kingdom
Ipsen

Completed

RELIEF Study: Lower Limb Pain Relief After Injection Cycles in Adults Suffering From Lower Limb Spasticity Following Stroke (RELIEF)

Lower Limb Spasticity

Spain
Ipsen

Completed

Study of Long-term Use of Forlax® in Elderly Patients With Chronic Constipation

Constipation

France
Ipsen

Completed

Cabozantinib Real-life Use for Advanced Renal Cell Carcinoma in France: a Retrospective Descriptive Non-interventional Study of 2 Cohorts. (CABOREAL)

Renal Cell Carcinoma

France
Ipsen

Completed

Efficacy, Safety and Tolerability of a New Bowel Cleansing Preparation (BLI800) in Adult Subjects Undergoing Colonoscopy (EASY)

Diagnosis Disease

China
Ipsen

Completed

Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg (PAMIS)

Prostate Cancer

Germany
Ipsen

Completed

Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer (Triptocare)

Prostate Cancer

Spain, Belgium, Netherlands, France, United Kingdom, Denmark, Latvia, Lithuania, Romania, Italy
Ipsen

Completed

The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer

Endometrial Cancer

Czechia, France, United Kingdom, Belgium, Latvia, Hungary, Lithuania, Moldova, Republic of, Poland, Russian Federation, Spain, Ukraine

3

Subscribe